- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05677334
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
May 6, 2023 updated by: First Affiliated Hospital of Guangxi Medical University
Study on the Efficacy and Safety of Henagliflozin Combined With Continuous Subcutaneous Insulin Infusion in the Treatment of Type 2 Diabetes Mellitus Based on Continuous Glucose Monitoring System
The Multi-center, randomized, controlled clinical trial investigate the efficacy and safety of Henagliflozin combined with continuous subcutaneous insulin infusion in newly diagnosed type 2 diabetes
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The therapeutic mechanisms of Sglt2i and continuous subcutaneous insulin infusion (CSII) are complementary.
We hypothesized that for newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia, combination treatment with Henagliflozin and CSII could achieve glycaemic control in a shorter time, shorten the duration of hospitalization and reduce the total insulin dosage.
We also hope to investigate the safety of sglt2i in combination with CSII in T2DM based on continuous glucose monitoring system.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yingfen Qin, Ph.D.
- Phone Number: 0771-5356517 13607862619
- Email: yingfenq@126.com
Study Contact Backup
- Name: Zhenxing Huang, Ph.D.
- Phone Number: 0771-5356517 13471009859
- Email: huangzx11@126.com
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Recruiting
- First Affiliated Hospital of Guangxi Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed as type 2 diabetes mellitus, diagnosis time ≤ 2 years
- Age between 20 and 70 years
- Continuous use of any hypoglycemic drug ≤ 7 days within 6 months
- 9% ≤ HbA1c ≤ 14% or fasting blood glucose ≥ 11.1 mmol/L
- Body mass index (BMI) of between 18 and 28 kg/m2
- Be able to understand the contents and methods of this study and sign the informed consent form voluntarily
Exclusion Criteria:
- Diabetic ketosis or ketoacidosis, diabetic hypertonic state, diabetic lactic acidosis and other acute diabetic complications or serious chronic diabetic complications
- Urinary tract infection or/and genital infection with clinical significance, or repeated urinary tract infection or/and genital infection history
- Serious trauma or acute infection occurred within 4 weeks that may affect blood glucose control
- People with negligent compensatory heart failure (NYHA grade III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, serious arrhythmia, cardiac surgery or vascular reconstruction within 6 months
- Serious blood system disease (such as aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or erythrocyte instability (such as malaria, hemolytic anemia)
- Severe chronic gastrointestinal diseases, or those who have received treatment that may affect drug absorption (such as gastrointestinal surgery)
- Uncontrolled hyperthyroidism
- Those who have mental or nervous system diseases and are unwilling to communicate or cannot fully understand and cooperate
- Pregnant or lactating women
- ALT>3.0x ULN and/or AST>3.0x ULN and/or Tbil>2.0x ULN Blood ketone body>ULN eGFR<30ml/min/1.73 m2 Blood creatine kinase>3.0x ULN
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Henagliflozin+ Continuous Subcutaneous Insulin Infusion
Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
|
Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
Other Names:
Continuous Subcutaneous Insulin Infusion therapy alone
|
Active Comparator: Continuous Subcutaneous Insulin Infusion
Continuous Subcutaneous Insulin Infusion therapy alone
|
Continuous Subcutaneous Insulin Infusion therapy alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time percentage (% TIR) in the range of 3.9~10.0 mmol/L blood glucose
Time Frame: Monitoring 7-14 days
|
Compare the TIR of the two treatment groups
|
Monitoring 7-14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time taken for TIR >70%
Time Frame: 7-14 days after treatment
|
Compare the time required for TIR >70% of the two groups
|
7-14 days after treatment
|
Mean Amplitude of Glycemic Excursions (MAGE)
Time Frame: 7-14 days after treatment
|
Compare the mage of the two treatment groups
|
7-14 days after treatment
|
time below range (TBR)
Time Frame: 7-14 days after treatment
|
Compare the TBR of the two treatment groups
|
7-14 days after treatment
|
total insulin dosage
Time Frame: 7-14 days after treatment
|
Compare the total insulin dosage of the two treatment groups
|
7-14 days after treatment
|
time above range (TAR)
Time Frame: 7-14 days after treatment
|
Compare the TAR of the two treatment groups
|
7-14 days after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yingfen Qin, First Affiliated Hospital of Guangxi Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2023
Primary Completion (Anticipated)
July 1, 2024
Study Completion (Anticipated)
August 1, 2024
Study Registration Dates
First Submitted
December 22, 2022
First Submitted That Met QC Criteria
January 9, 2023
First Posted (Actual)
January 10, 2023
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 6, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-K148-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2diabetes
-
University of Erlangen-Nürnberg Medical SchoolBayerRecruiting
-
Chong Kun Dang PharmaceuticalCompletedType2DiabetesKorea, Republic of
-
University of ManitobaDiabetes Canada; Children's Hospital Research Institute of Manitoba (CHRIM)Active, not recruitingPrevention | Type2DiabetesCanada
-
Methodist Health SystemActive, not recruitingDiabetes | Type2diabetesUnited States
-
Universidade Nova de Lisboacruz vermelha hospitalRecruitingObesity | Bariatric Surgery Candidate | Metabolic Disease | Type2diabetesPortugal
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruiting
-
Adrian VellaRecruiting
-
Bozok UniversityRecruitingDiabetes Mellitus | Stress | Motivational Interviewing | Type2diabetes | Well-Being, PsychologicalTurkey
-
Tel Aviv UniversityNot yet recruiting
-
Wake Forest University Health SciencesAmerican Diabetes AssociationRecruiting
Clinical Trials on Henagliflozin
-
Qian gengRecruitingMyocardial Infarction | Heart FailureChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Beijing Anzhen HospitalNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
The First People's Hospital of ChangzhouThe First Affiliated Hospital of Soochow University; Second Affiliated Hospital... and other collaboratorsNot yet recruitingWeight Loss | Obese | Pre-diabetes
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Qianfoshan HospitalNot yet recruitingDiabetic Nephropathies
-
Sir Run Run Shaw HospitalNot yet recruitingType 2 Diabetes | Non-Alcoholic Fatty Liver Disease